The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients

Inclusion Criteria: * Age ≥ 18 years at time of transplantation. * Undergoing first-time deceased-donor kidney transplantation. * No administration of proton-competitive acid blockers (P-CABs) in the 1 month prior to transplantation. * Consent to receive the standard immunosuppressive therapy post-transplantation. * Ability and willingness to provide informed consent and comply with study procedures and follow-up. * Complete baseline clinical data available. Exclusion Criteria: * Receiving a living-donor kidney transplant or multi-organ transplantation. * Previous history of any solid organ or cellular transplantation (with the exception of corneal transplants). * Intraoperative occurrence of hyperacute rejection or confirmed graft non-function (e.g., renal artery thrombosis). * Presence of high risk for primary graft non-function (e.g., severe injury to the transplant renal artery). * Severe postoperative intestinal obstruction requiring prolonged fasting or inability to take oral medication in perioperative period. * Known history of hypersensitivity to vonoprazan fumarate or any of its excipients. * Subjects with severe hepatic impairment (Child-Pugh Class C). * Concomitant use of strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin). * Current therapy with atazanavir or rilpivirine. * Any other condition deemed by the investigator to be inappropriate for study participation (e.g., uncontrolled active infection, severe peptic ulcer, pregnancy or lactation).